Amniotics AB (publ) Announces Resignation of Board Member

About Amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University HospitalUniversity Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA in Sweden), approved GMP (Good Manufacturing Practice (GMP) manufacturing facility to produce Advanced therapy Therapy medicinal Medicinal products Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics has itsit´s headquarter in Lund, Sweden.

Amniotics (publ) has it´s headquarter in Lund, Sweden.

Amniotics Certified Adviser on First North is Redeye AB, [email protected], telephone: +46 (0) 8 121 576 90.

The company is listed at Nasdaq First North Growth Market in Stockholm.
Learn more at www.amniotics.com.